Currently out of the existing stock ratings of Colin Bristow, 83 are a BUY (58.04%), 60 are a HOLD (41.96%).

Colin Bristow

Work Performance Price Targets & Ratings Chart

Analyst Colin Bristow, carries an average stock price target met ratio of 59.45% that have a potential upside of 24.95% achieved within 205 days. Previously, Colin Bristow worked at UBS.

Colin Bristow’s has documented 288 price targets and ratings displayed on 22 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on VRTX, Vertex Pharmaceuticals at 05-Aug-2025.

Wall Street Analyst Colin Bristow

Analyst best performing recommendations are on ENGN (ENGENE HOLDINGS COMMON STOCK).
The best stock recommendation documented was for IMVT (IMMUNOVANT ) at 9/26/2022. The price target of $5 was fulfilled within 3 days with a profit of $0.48 (10.62%) receiving and performance score of 35.4.

Average potential price target upside

of $150.89 (18.03%) on REGN (REGENERON PHARMACEUTICALS).
of $127.12 (44.22%) on BTAI (BIOXCEL THERAPEUTICS).
of $65.34 (23.03%) on VRTX (VERTEX PHARMACEUTICALS).

ALXN Alexion Pharmaceuticals AMGN Amgen BIIB Biogen BTAI BioXcel Therapeutics GILD Gilead Sciences LLY Eli Lilly and Company MRK Merck mpany MTEM Molecular Templates OMER Omeros PFE Pfizer PTCT PTC Therapeutics SRPT Sarepta Therapeutics VRTX Vertex Pharmaceuticals ABBV AbbVie CCCC C4 Therapeutics BMY Bristol-Myers Squibb Company RCKT Rocket Pharmaceuticals ALXO Alx Oncology Holdings IMVT Immunovant REGN Regeneron Pharmaceuticals ABOS Acumen Pharmaceuticals ENGN enGene Holdings Common Stock

Show more stocks

Analyst name

Rating

Rating initiation date

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score